SBIR Phase I: FRET-Aptamer Tests for Treated Wastewater

SBIR 第一阶段：处理废水的 FRET 适体测试

• 批准号: 0839260
• 负责人: John Bruno
• 金额: $ 10万
• 依托单位: Operational Technologies Corporation
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-01-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=0839260&HistoricalAwards=false
• 关键词: SBIR; Phase; FRET; Aptamer; Tests

This Small Business Innovative Research (SBIR) Phase I project proposes to further develop its one-step fluorescence resonance energy transfer (FRET)-DNA aptamer technology for the rapid (assay results within minutes of sampling), sensitive, on-site detection of fecal bacteria in treated water supplies. Operational Technologies Corporation (OpTech) previously demonstrated successful development of FRET-aptamers that bind common core antigens of surface molecules from various strains of E. coli and used the preliminary family of FRET-aptamers to detect as few as 10 bacteria per milliliter in water samples with a commercial-off-the-shelf (COTS)handheld and battery-operated fluorescence sensor. The technology was in development to satisfy stringent requirements of the federal Beaches Act, but is now proposed as a broader solution for safety verification of treated wastewater. In order to meet this new requirement, OpTech will add a fluorescence viability test for the handheld reader and compare to standard Colilert fluorescence test results. In Phase II, OpTech will expand its repertoire of tests to include other enteric bacteria, viruses, and parasites.The broader impacts of this research are: 1) enhanced drinking water safety for the public 2)better on-site decision making ability for wastewater treatment facilities to decide if treated effluents are suitable for drinking, irrigation, or release back into the environment, 3) faster decision making ability at recreational waters (oceans, lakes, even swimming pools) with regard to potential closings to prevent human exposure to fecal contamination. FRET-aptamer technology also has applications in rapid and portable food safety testing, homeland security, and clinical point-of-care diagnostics.

该小型企业创新研究 (SBIR) 第一阶段项目建议进一步开发其一步式荧光共振能量转移 (FRET)-DNA 适体技术，用于快速（采样后几分钟内即可得出检测结果）、灵敏的现场检测处理后的供水中的粪便细菌。 Operational Technologies Corporation (OpTech) 此前展示了 FRET 适配体的成功开发，该适配体可结合来自不同大肠杆菌菌株的表面分子的共同核心抗原，并使用初步的 FRET 适配体系列，通过商用现成 (COTS) 手持式电池供电荧光传感器检测水样中低至每毫升 10 个细菌。该技术的开发是为了满足联邦海滩法案的严格要求，但现在被提议作为处理废水安全验证的更广泛的解决方案。为了满足这一新要求，OpTech 将为手持式读数器添加荧光活力测试，并与标准 Colilert 荧光测试结果进行比较。在第二阶段，OpTech 将扩大其测试范围，包括其他肠道细菌、病毒和寄生虫。这项研究的更广泛影响是：1) 增强公众的饮用水安全 2) 提高废水处理设施的现场决策能力，以确定处理后的废水是否适合饮用、灌溉或释放回环境中，3) 提高休闲水域（海洋、湖泊，甚至游泳）的决策能力 池）关于可能关闭以防止人类接触粪便污染的问题。 FRET 适体技术还应用于快速便携式食品安全检测、国土安全和临床护理点诊断。